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The human N-terminal acetyltransferase E (NatE) contains NAA10 and NAA50 catalytic, and
NAA15 auxiliary subunits and associates with HYPK, a protein with intrinsic NAA10 inhibitory
activity. NatE co-translationally acetylates the N-terminus of half the proteome to mediate
diverse biological processes, including protein half-life, localization, and interaction. The
molecular basis for how NatE and HYPK cooperate is unknown. Here, we report the cryo-EM
structures of human NatE and NatE/HYPK complexes and associated biochemistry. We
reveal that NAA50 and HYPK exhibit negative cooperative binding to NAA15 in vitro and in
human cells by inducing NAA15 shifts in opposing directions. NAA50 and HYPK each con-
tribute to NAA10 activity inhibition through structural alteration of the NAA10 substrate-
binding site. NAA50 activity is increased through NAA15 tethering, but is inhibited by HYPK
through structural alteration of the NatE substrate-binding site. These studies reveal the
molecular basis for coordinated N-terminal acetylation by NatE and HYPK.
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Protein N-terminal acetylation is one of the most ubiquitouscovalent modifications among eukaryotes, occurring on~80% of human proteins1,2. This modification affects many
protein functions, including protein half-life, folding, complex
formation, and localization1,3–10. Protein N-terminal acetylation
is considered an irreversible process and is catalyzed by N-
terminal acetyltransferases (NATs). In human, seven different
NATs with different subunit composition and substrate pre-
ferences have been identified to date, including hNatA through
hNatH11, with the exception that NatG is only present in
chloroplasts of plant cells12. NatA, NatB, and NatC are three
major NATs, each consisting of a catalytic subunit and one (NatA
and NatB) or two (NatC) auxiliary subunits11,13. The NatE
complex contains NatA and an additional catalytic subunit,
NAA5014,15. NatD, NatF, and NatH function in the absence of an
auxiliary subunit. NatA acetylates non-methionine containing
substrates harboring small N-terminal residues (alanine, serine,
threonine, cysteine, and valine)2,16. NatB/C/E/F modify proteins
with N-terminal methionine residues: NatB acetylates methionine
followed by a negatively charged residue17,18, while NatC/E/F
acetylate methionine followed by hydrophobic/amphipathic
residues5,15,19–22. NatD and NatH exhibit highly selective sub-
strate recognition patterns; NatD acetylates only the N-terminus
of histones H2A and H423,24, while NatH acts solely on processed
actins25,26. NatA through NatE function predominantly co-
translationally through association with the ribosome27, while
NatF anchors onto the Golgi membrane to acetylate transmem-
brane proteins20,28,29.
About one-half of the human N-terminal acetylome is mediated
by hNatA. Mutations in either the hNAA10 catalytic or hNAA15
auxiliary subunits have been correlated with a broad spectrum of
pathologies, including intellectual disabilities, developmental
delay, autism spectrum disorders, craniofacial dysmorphology,
congenital cardiac anomalies, and Ogden syndrome30–39. Aber-
rant NatA activity has also been correlated with neurodegenerative
disorders and cancer although a causative role of NatA is less
clear40. NatA forms complexes with at least two other proteins,
NAA50 and the chaperone protein Huntingtin-interacting protein
K (HYPK)14,41–44. The trimeric hNAA10/hNAA15/hNAA50
complex is referred to as hNatE, and we refer to the tetrameric
hNAA10/hNAA15/hNAA50/HYPK complex as hNatE/HYPK.
Previous studies have demonstrated that HYPK may be important
for cellular NatA activity and that NAA50 and NatA can affect
each other’s function16,41,44–46. Previous studies also demon-
strated that hNatA can physically associate with hNAA50 (ref. 14)
and HYPK (ref. 41), separately. Moreover, the crystal structures of
hNatA with HYPK and related pull-down experiments indicated
that HYPK and hNAA50 binding to hNatA might be mutually
exclusive16. However, another study suggested that HYPK and
NatE form a tetrameric complex in Drosophila cells45.
To delineate the mechanistic basis for how the NAA10 and
NAA50 catalytic subunits of the NatE complex coordinate function
and how this is regulated by HYPK, we characterized the human
NatE and NatE/HYPK complexes biochemically, structurally, and
in cells. We show that hNAA50 and HYPK exhibit negative
cooperative binding to hNatA in vitro and in human cells, by
inducing hNAA15 shifts in opposing directions. We show that
hNAA50 and HYPK both mediate hNAA10 inhibition through
structural alteration of the hNAA10 substrate-binding site. We
show that hNatE is about tenfold more active than hNAA50, likely
due to a reduced entropic cost for substrate-binding through hNatA
tethering, but is inhibited by HYPK through structural alteration of
the hNatE substrate-binding site. Taken together, these studies
reveal the molecular basis for coordinated N-terminal acetylation by
the hNAA10 and hNAA50 catalytic subunits of NatE and its
modulation by HYPK.
Results
hNatE and HYPK form a tetrameric complex. To determine if
human NAA50 and HYPK can simultaneously bind to NatA to
form a hNatE/HYPK complex, we prepared the recombinant
hNatA/HYPK complex from insect cells and mixed it with
recombinant hNAA50 for analysis on size-exclusion chromato-
graphy (Fig. 1a—left). Analysis of the peak fractions on sodium
dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE)
revealed that the four protein components (hNAA10, hNAA15,
hNAA50, and HYPK) co-eluted in a single major peak with
excess hNAA50 eluting in later fractions (Fig. 1a). This result
demonstrates that HYPK and hNAA50 can bind to hNatA
simultaneously to form a tetrameric hNatE/HYPK complex.
HYPK and hNAA50 display negative cooperative binding to
hNatA. Previous studies demonstrated that both human HYPK
and hNAA50 bind tightly to hNatA, with dissociation constants
in the nanomolar range16,46. We set out to determine if the
HYPK- and hNAA50 binding properties to hNatA are altered in
the context of the tetrameric complex. Using fluorescence
polarization (FP) assays, we observed that hNAA50 bound to
hNatA with a Kd of 46 ± 8.8 nM (Fig. 1b), consistent with pre-
vious results. However, in the presence of maltose-binding pro-
tein (MBP) tagged HYPK (MBP-HYPK), this binding Kd
decreased about threefold to 127 ± 13 nM (Fig. 1b). This data
demonstrates that HYPK can negatively affect the stability of the
hNatE complex by about threefold. Based on this data, we
hypothesized that in the presence of hNAA50, the binding affinity
between hNatA and HYPK would also decrease. Using isothermal
titration calorimetry (ITC), we determined that the Kd between
hNatA and MBP-HYPK was 29.9 ± 16.7 nM (Fig. 1c), which is
consistent with the previously reported Kd in the thermophilic
fungus Chaetomium thermophilum44. The reason for the appar-
ent two-binding transition when HYPK is titrated into hNatA is
unknown. We further determined the Kd between HYPK and
hNatE, and observed that the affinity was 154.1 ± 55.3 nM,
approximately fivefold weaker than HYPK binding to hNatA
(Fig. 1d). A control ITC run of MBP titrated into hNatA failed to
show binding (Supplementary Fig. 1). Taken together, these data
indicate that HYPK and hNAA50 display negative cooperative
binding with respect to hNatA.
hNAA50 and HYPK inhibit hNatA activity, and HYPK is
dominant. While our previous studies demonstrated that yeast
and human NatA have slightly elevated catalytic efficiencies in the
presence of NAA50, we set out to make a more direct comparison
of NatA activity as a function of added NAA50 vs. HYPK. To do
this, we used an in vitro acetylation assay using a cognate SASE
NatA substrate (Ser-Ala-Ser-Glu; for full sequence see Methods)
to compare the hNatA catalytic activity as a function of added
hNAA50 or MBP-HYPK. This comparison revealed that while
MBP-HYPK showed ~90% inhibition of hNatA activity at an
MBP-HYPK concentration beyond ~100 nM, hNAA50
only decreased hNatA activity by ~50% at concentrations
between ~100 nM and 1 µM (Fig. 2a), consistent with the pre-
vious data16,46. Titrating both MBP-HYPK and hNAA50 into
hNatA showed a similar degree to hNatA inhibition as did
titrating in MBP-HYPK alone, illustrating that HYPK inhibition
of hNatA overrides the incomplete inhibitory effect of hNAA50
(Fig. 2a).
HYPK inhibits hNatE activity. Given that HYPK was shown to be
a negative regulator for hNatA acetylation activity16,44, we asked if it
also inhibited the activity hNatE. To do this, we used the same
in vitro acetyltransferase activity assay but employed a cognate
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MLGP hNatE substrate (Met-Leu-Gly-Pro; for full sequence see
Methods) in the absence or presence of HYPK, as well as a
hNAA50 only control. This analysis revealed that while hNatE was
more active than hNAA50, this improvement was essentially nul-
lified with the addition of HYPK (Fig. 2b–d). A full kinetic analysis
of hNAA50, hNatE, and hNatE/HYPK revealed the kinetic para-
meters responsible for this modulation of hNAA50 function. Spe-
cifically, we found that hNatE displayed ~8.6-fold decrease of Km,
and ~1.1-fold decrease of kcat, with an overall ~7.7-fold increase of
catalytic efficiency, compared to hNAA50 (Table 1). These findings
are in general agreement with the previous studies with the
orthologous yeast proteins46. A comparison of the activities of
hNatE and hNatE/HYPK revealed that in the presence HYPK,
hNatE displayed an ~1.3-fold decrease in Km, and an ~3.8-fold
decrease in kcat, with an overall ~2.9-fold decrease in catalytic
efficiency (Table 1). This data suggests that HYPK can compromise
hNatE activity. Taken together, while hNatA significantly enhances
the catalytic efficiency of hNatE, HYPK binding to hNatE largely
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Fig. 1 HYPK and hNatE form a tetrameric complex. a Left—gel filtration elution profile of the hNatA/HYPK complex with excess hNAA50, using a
Superdex S200 column. Right—Coomassie-stained SDS–PAGE of peak fractions. Red bars indicates the peak complex. b Fluorescence polarization assays
with either hNatA or hNatA/MBP-HYPK titrated into fluorescein-5-maleimide-labeled hNAA50. The data is fit to calculate a dissociation constant (Kd).
Replicates were shown in the curve with n= 3 independent experiments. Source data are provided as a Source Data file. c Representative ITC curve of
MBP-HYPK titrated into hNatA. The calculated Kd is indicated. d Representative ITC curve of MBP-HYPK titrated into hNatE. e The ITC fitting information
and calculated Kd is provided for curves c and d.
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hNatA forms competing complexes with hNAA50 and HYPK
in cells. To further confirm the existence of the tetrameric hNatE/
HYPK complex observed in vitro in human cells, we immuno-
precipitated hNAA15 (c-terminal V5 tagged) from HeLa cells to
evaluate the associated proteins. Mass spectrometry (MS) analysis
of this sample revealed that endogenous hNAA10, hNAA50, and
HYPK were all co-immunoprecipitated with NAA15-WT-V5, in
agreement with the tetrameric hNatE/HYPK complex formation
(Fig. 3a, Supplementary Fig. 2).
In prior studies, we reported that a hNAA15-T406Y mutant can
disassociate hNAA50 from hNatA in vitro46, while a hNAA15-
L814P mutant is defective for HYPK inhibition and reduces hNatA
thermostability37. Based on these observations, we also carried out a
MS analysis of the V5 immunoprecipitates of the hNAA15-T406Y-
V5 and hNAA15-L814P-V5 mutants to evaluate the effect of the
mutation’s on formation of the hNatE/HYPK tetrameric complex
(Supplementary Data 1). For relative quantification of the hNatA
proteins, the intensity-based absolute quantification (IBAQ)
intensities of the hNatA components in each sample were
normalized to the IBAQ intensity of hNAA15 in the respective
sample and to the corresponding protein in the (wild-type) WT
sample (Fig. 3a, Supplementary Data 1). This analysis demonstrated
that hNAA15-T406Y-V5 and hNAA15-L814P-V5 had reduced
binding of hNAA50 and HYPK respectively, indicating that the
mutations negatively affected the ability of hNAA15 to bind
hNAA50 and HYPK, respectively. Furthermore, it appeared that the
reduced binding of HYPK or hNAA50 resulted in greater binding
of the other component: hNAA15-T406Y-V5 bound less hNAA50,
but more HYPK than hNAA15-WT, while hNAA15-L814P-V5
bound less HYPK and more hNAA50 than hNAA15-WT (Fig. 3a,
Supplementary Data 1, Supplementary Fig. 2). These observations
are in agreement with the in vitro FP and ITC assays,
demonstrating that HYPK and hNAA50 display negative coopera-
tive binding with respect to hNatA. Taken together, these cellular
studies agree with the in vitro studies by confirming the existence of
the tetrameric hNatE/HYPK complex, and indicating that HYPK
and hNAA50 display negative cooperative binding with respect
to hNatA.
The intrinsic hNatA catalytic activities of the hNAA15-T406Y-
V5 and hNAA15-L814P-V5 variants were also tested in a Nt-
acetylation assay and western blot (Fig. 3b, Supplementary Fig. 3).
Importantly, equal levels of hNAA10 was pulled out with the
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Fig. 2 HYPK binding negatively affects hNatE acetylation activity. a Either MBP-HYPK (green), hNAA50 (red), or both (blue) are titrated into hNatA
(100 nM) to evaluate their modulatory effect on hNatA activity against an SASE peptide substrate. A best line is drawn through the data points for ease of
visualization. Source data are provided as a Source Data file. b Comparison of time course acetylation activity of hNAA50 (black), preformed hNatE (red),
and preformed hNatE/HYPK (blue; all 500 nM) against an MLGP peptide substrate. Source data are provided as a Source Data file. c hNatA acetylation
activity against an SASE peptide with addition of buffer, wild type (WT), or hNAA50 mutants. Errors were reported in SEM with n= 3 independent
experiments. Source data are provided as a Source Data file. d Activity of hNAA50WT and mutants against MLGP peptide was tested, either alone (black),
in the context of hNatE (+hNatA; red), or in the context of preformed hNatE/HYPK (+hNatA/HYPK; blue). Data were normalized to WT hNatE activity as
100%, represented as mean ± SD, n= 3 independent experiments. Source data are provided as a Source Data file.
Table 1 Catalytic parameters for hNAA50, hNatE, and
hNatE/HYPK.
kcat (min−1) Km (μM) kcat/Km (μM−1
min−1)
hNAA50* 3.45 831.5 4.15 × 10−3
hNatE* 3.09 96.2 3.21 × 10−2
hNatE/HYPK 0.81 73.1 1.11 × 10−2
*Calculation of kinetic parameters for hNAA50 and hNatE is based on an independent replicate
of experiments previously reported46. Source data are provided in the Source Data file.
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mutants affect hNAA10 binding. The hNAA15-T406Y-V5 hNatA
complex displayed a decreased catalytic activity toward the
hNatA substrate SESS24 compared to WT hNatA. This could be
explained by an increased binding and inhibitory effect of HYPK
and/or due to the reduced binding of hNAA50. The hNAA15-
L814P-V5 hNatA complex showed an increased catalytic activity
compared to WT hNatA, which is consistent with the in vitro
findings of reduced binding of HYPK and consequently less
inhibition of the catalytic activity and/or an increased binding of
hNAA50.
hNatE structure reveals molecular basis for enzyme crosstalk.
To determine the molecular basis for interaction and enzymatic
crosstalk between human NAA10 and NAA50 enzyme subunits
within the NatE complex, we determined the single-particle
cryogenic electron microscopy (cryo-EM) structure of the hNatE
complex in the presence of inositol hexakisphosphate IP6 and bi-
substrate analogs of both hNatA and hNAA50. The model of the
human complex was rigid body fitted with the coordinates of the
crystal structure of hNatA (PDB: 6C9M) and hNAA50 (PDB:
3TFY), with all ligands removed. After refinement of the model,
we observed clear density of IP6 and acetyl-CoA cofactors in each
catalytic subunit, but the peptide portion of the bi-substrate
inhibitors was not resolved. The structure was refined to an
overall resolution of 3.0 Å, with most residues of hNAA10 and
hNAA50 subunits resolved to 2.5 Å (Supplementary Figs. 4, 5, 6,
and 7). The refinement statistics can be found in Table 2. The N-
terminal 112 residues of hNAA15 subunit were not modeled due
to a lack of traceable cryo-EM density for this region.
Consistent with the previous studies with the orthologous yeast
proteins46, hNAA50 predominantly interacts with hNAA15 (α21,
α22, α23, and α24), and makes relatively few interactions with
hNAA10 (Fig. 4a), burying a solvent excluded surface of 34,316 Å2
with hNAA15, and 9100 Å2 with hNAA10. Based on the structure
of the ScNatE complex, a hNAA15-T406Y mutant was shown to
disrupt the hNatA-NAA50 interaction46. Indeed, we find that
hNAA15-Thr406 is located at the center of the hNAA50-hNAA15
interface, making hydrogen bond interactions with the backbone
carbonyl group of hNAA50-Ala55 (Fig. 4b). Additional hydrogen
bonds are formed between the backbone carbonyl of hNAA50-
His14 with the backbone amide of hNAA15-Thr439, between
hNAA50-Arg21 and the backbone carbonyl of hNAA15-Pro405,
and between hNAA50-Asn52 and hNAA15-Thr371 (Fig. 4b).
hNAA50-Arg21 also makes direct ionic interaction with hNAA15-
Glu433, which is absent in yeast (Fig. 4b). It is possible that this
ionic interaction underlies the increased salt sensitivity of the
human vs. yeast NatE complex46. Interestingly, we do not observe
significant hydrophobic interactions at the hNAA15-hNAA50
contact interface.
hNAA50-hNAA10 interactions are less extensive than
hNAA50-hNAA15, yet still significant. Interactions are observed
between hNAA50-Glu7 and hNAA10-Arg116, and between
hNAA50-Asp53 and hNAA10-Arg83 (Fig. 4c). This structural
observation highlights the recent identification of a missense
mutation of hNAA10 R83H that exhibits decreased acetylation
activity in boys with intellectual disability and developmental
delay38. It is noteworthy that hNAA10-Arg83 also makes
interaction with the 3′ phosphate of the acetyl-CoA molecule
bound to hNAA10 (Fig. 4c).
To assess the importance of the NatA-NAA50 interactions on
the catalytic crosstalk of the two enzymes, we prepared hNAA50-
E7A, -D53A and -E7A/D53A mutants and evaluated their effect
on hNatA activity (Fig. 2c). We found that the single and double
mutants were able to restore between 12–17% of hNatA activity
relative to the activity of hNatA bound to WT-hNAA50 (Fig. 2c).
These results demonstrate that the observed hydrogen bond
interactions between hNatA and hNAA50 make a small, albeit
significant, contribution to the catalytic crosstalk between the two
enzymes.
An overlay of the Saccharomyces cerevisiae (PDB: 6O07) and
human NatE structures reveals a high degree of structural
conservation with a root-mean square deviation (RMSD) of 1.517
Å (over 622 common Cα atoms). However, it is noteworthy that
when bound to NatA, we observe that NAA50 shifts significantly
closer to NAA10 in the human over the yeast complex, resulting in
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Fig. 3 hNatA forms competing complexes with hNAA50 and HYPK. a Heat map showing the mean relative IBAQ intensity of NatA components from
three independent MS analyses of immunoprecipitated NAA15 variants, NAA15-WT-V5, NAA15-T406Y-V5, and NAA15-L814P-V5. The IBAQ intensities
of each component were normalized to the IBAQ intensity of NAA15 in the respective sample and to the corresponding NatA WT protein. Source data are
provided as a Source Data file. b Western blot analysis and NatA Nt-acetylation assay of V5-immunoprecipiated NAA15 variants. The measured DPM
signal for each reaction was normalized to the corresponding V5-band in the IP. The immunoprecipitation and activity assay were performed in n= 3
independent experiments, each with three technical replicates (indicated by dot plots) per assay. Source data are provided as a Source Data file.
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human complex (Fig. 5a). α3 and β7 of hNAA50 shift toward
hNAA10 ~10 Å and 11 Å, respectively (Fig. 5a). Such significant
shift in hNAA50 position relative to hNatA is surprising and may
reflect a functional importance when these proteins are associated
with the ribosome (Discussion section).
To understand other structural contributions that hNAA50
might have on hNatA activity, we superimposed the hNatE
structure with the hNatA crystal structure (PDB: 6C9M). We
found that hNAA15 and hNAA10 in the ternary hNatE complex
displayed an RMSD of 0.747 Å (over 624 common Cα atoms),
and 0.897 Å (over 141 common Cα atoms), respectively (Fig. 5b).
The hNAA10 β6–β7 loop displayed about a 4 Å shift toward
hNAA50 in the hNatE complex relative to the hNatA complex
(Fig. 5b). Given that the β6–β7 loop of hNAA10 plays an
important role in peptide substrate recognition, we propose that
this shift in position also contributes to the inhibitory effect that
hNAA50 binding has on hNatA activity.
To understand the molecular basis for why hNatA binding
increases the catalytic efficiency of hNatE by nearly eightfold
(Fig. 2b, Table 1), we superimposed the hNAA50 crystal structure
(PDB: 3TFY) with the hNAA50 subunits of the hNatE structure.
Remarkably, we did not observe any significant structural changes
in hNAA50 with an overall RMSD for all atoms of 0.437 Å
(Fig. 5b). Notably, the β6–β7 and α1–α2 peptide substrate-
binding loops of hNAA50 within the hNatE complex super-
imposed well with hNAA50 bound to CoA and substrate peptide
(Fig. 5b). Based on this observation, we hypothesize that the
increased activity of hNatE is due to a reduced entropic cost for
substrate binding to the hNAA50 subunit due to hNatA tethering.
This is consistent with the observations of Wand and colleagues
for other protein systems47.
hNatE/HYPK structure reveals negative cooperative mechan-
ism. To obtain a molecular understanding of how hNAA50 and
HYPK can both bind hNatA, we determined the structure of the
hNatE/HYPK complex by cryo-EM, which we were able to
resolve to an overall resolution of 4.0 Å (Supplementary Figs. 4–
7). The starting structure was modeled using the hNatA/HYPK
(PDB: 6C95) and hNAA50 (PDB: 3TFY), which were placed into
the cryo-EM map through rigid body fitting, followed by
adjustment and refinement. The refinement statistics can be
found in Table 2.
In the tetrameric structure, we observe that both hNAA50 and
HYPK simultaneously dock onto the same binding regions on
hNatA, as previously identified in the absence of the other
protein16. While both hNAA50 and HYPK contact both subunits
of hNatA, no direct interactions are observed between hNAA50
and HYPK (Fig. 6a). HYPK binds NatA mainly through
interactions with the hNAA15 subunit of hNatA: only the α1
helix of HYPK interacts with hNAA10, while the α2 and C-
terminal UBA domain (α3, α4, and α5 helices) of HYPK interact
with hNAA15 (Fig. 6a). Previous studies demonstrated that the
UBA domain and α2 helix play key roles in hNatA binding, while
α1 is essential for hNatA activity inhibition16,44.
Over the HYPK and hNatA interaction interface within the
tetrameric complex, we observe polar interactions between
HYPK-Glu74 and hNAA15-Tyr158, between the backbone
carbonyl of HYPK-Thr100 and hNAA15-Lys687, between the
backbone carbonyl of HYPK-Asn129 and hNAA15-Arg697, and
between HYPK-Asn129 and hNAA15-Lys696, which were all
observed similarly in the hNatA/HYPK crystal structure16
(Fig. 6b). However, HYPK-Glu103, hNAA15-Lys685, and
hNAA15-Glu655 which form a salt bridge in the hNatA/HYPK
structure do not show a similar contact in the tetrameric hNatE/
HYPK complex16 (Fig. 6b). We speculate that the absence of this
interaction might contribute to the slightly weaker affinity of
HYPK for hNatE over hNatA.
hNAA15 and hNAA50 also make similar interactions in the
absence or presence of HYPK. The backbone carbonyl of
hNAA50-His14 hydrogen bonds with the backbone amide of
hNAA15-Thr439, and hNAA50-Asn52 hydrogen bonds with
hNAA15-Thr371 (Fig. 6c). Interestingly, however, a key residue
that stabilizes the hNatA-hNAA50 interaction, hNAA15-Thr406
shifts from in interaction with the carbonyl of hNAA50-Ala55 to
a hydrogen bond to the hNAA50-Gln18 side chain in the
tetrameric complex (Fig. 6c). An additional H-bond is formed
between hNAA50-Gln18 and the backbone carbonyl of hNAA15-
Thr406 (Fig. 6c). hNAA50-Arg21, a residue that makes extensive
contacts to NAA15 in the hNatA/NAA50 complex (Fig. 4b) is
only contacting hNAA15-Glu433 in the tetrameric complex
(Fig. 6c). In addition, while hNAA50-Asp53 and hNAA10-Arg83
maintain interaction as observed in the hNatA/hNAA50 complex,
hNAA50-Glu7 and hNAA10-Arg116 lose interaction in the
tetrameric complex (Fig. 6d). These observations correlate with
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the observed weaker binding interaction between hNAA50 and
hNatA in the presence of HYPK.
To understand the molecular basis for the biochemical findings
that the binding of hNAA50 and HYPK to hNatA exhibit negative
cooperativity, we superimposed the ternary hNatA/HYPK and
hNatE complexes onto the hNatE/HYPK complex (Fig. 7). To
align the hNatE and hNatE/HYPK complexes, we superimposed
the hNAA50 position to delineate how the HYPK binding regions
are affected by hNAA50 binding (Fig. 7a). The overall overlay
suggests that both the hNAA10 and hNAA15 subunits of hNatA
shift in the direction that is away from the hNAA50 binding
region to make closer and more optimal contacts with HYPK
(Fig. 7a). The hNAA15 α36–α40 helices, which bind to the C-
terminal UBA domain (α3–α5) of HYPK in the tetrameric hNatE/
HYPK complex, clearly shift away from the binding interface,
when only hNAA50 is bound to hNatA (Fig. 7c). Notably, α40,
α38, α37, and α36 display shift of ~4.5 Å, ~2.3 Å, ~1.6 Å, and
~1.8 Å, respectively. The important residues of hNAA15 (Lys696,
Arg697, Lys687, and Lys685), which mediate HYPK interactions
in this region suggested that most of them in the hNatE structure
exhibit an ~ 2 Å shift away from HYPK (Fig. 7c). Meanwhile,
hNAA15 N-terminal helices of α7, α8, α9, and α10, which are in
close contact with HYPK-α2 also show ~3.0 Å, ~4.1 Å, ~1.9 Å, and
~3.5 Å shifts, respectively (Fig. 7d), while Tyr158 is about ~2 Å
further away. Lastly, we observe that α2 and β3–β4 of hNAA50-
bound hNAA10 move ~2.5 Å closer to contact the HYPK N-
terminal α1 helix (Fig. 7e). Thus, it appears that hNAA50 binding
to hNatA, destabilizes hNatA-HYPK interactions through moving
hNatA away from its optimal binding position to HYPK.
Similarly, a superposition of hNatE/HYPK with the crystal
structure of hNatA/HYPK by aligning to the HYPK position to
delineate how the hNAA50 binding regions are affected by HYPK
binding reveals that hNAA15 is shifted away from HYPK and
closer to hNAA50 in the hNatE/HYPK complex (Fig. 7b). A
further zoom-in view of the hNAA50 binding regions in hNAA15
demonstrates that residues Glu433, Thr406, Thr371, and Thr439
of hNAA15 are shifted by ~2− 3 Å away from hNAA50 when
HYPK is bound relative to their positions in the absence of
hNAA50 (Fig. 7f). Regarding the hNAA50-hNAA10 binding
interface, a 4.3 Å shift of hNAA10-Arg116 was observed, with a
1.7 Å for hNAA10-Arg83 (Fig. 7g). It is also noteworthy that
significant conformational shift of the C-terminal hNAA15
helices α41–α45(~2.2− 4.2 Å) was induced, in order to have
hNAA50 bound in the tetrameric hNatE/HYPK complex
(Fig. 7h). This suggests that HYPK bound hNatA is also not
optimal for hNAA50 binding.
Taken together, these comparisons reveal that hNAA50 and
HYPK destabilize the binding of the other protein to hNatA,
despite their independent binding surfaces to hNatA, and explain
the observed negative cooperative binding of hNAA50 and HYPK
to hNatA.
Molecular basis for decrease of hNatE activity by HYPK. Our
kinetic data demonstrated that the catalytic efficiency of hNatE
is greater than hNAA50, but that this increase is partially
nullified in the presence of HYPK (Table 1, Fig. 2b). To
understand the molecular basis for this, we overlayed structures














































Fig. 4 Cryo-EM structure of the hNatE complex. a hNAA50(magenta), hNAA15(green), and hNAA10(orange) within the hNatE complex shown in
cartoon. b Zoom-in view of the contacts between hNAA15 and hNAA50 with residues that participate in interaction labeled. c Zoom-in view of the
contacts between hNAA10 and hNAA50 with residues that participate in interaction shown. Acetyl-CoA bound to hNAA10 is shown in ball and stick.
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aligned. This superposition reveals that the largest structural
differences within the hNAA50 subunit map to the β6–β7 and
α1–α2 loops, which shift such that the hNAA50 peptide
substrate-binding groove is ~2.4 Å wider in the hNatE/HYPK
complex relative to the hNatE complex (Fig. 8). In addition, the
hNAA50 β3–β4 loop is shifted in the direction away from
hNatA by ~3.5 Å in the presence of HYPK (Fig. 8). The pre-
vious studies demonstrated that Tyr73 and Met75 from
hNAA50-β4 and Tyr138, Tyr139 and Leu142 from the hNAA50
β6-β7 loop are important for hNAA50 catalytic function and
substrate binding21. To directly test this, we prepared the fol-
lowing mutants: hNAA50-Y73F, -M75A, -Y138A, -Y139A, and
-I142A, and tested their effects on hNatE activity when HYPK
was bound (Fig. 2d). Consistent with the previous studies,
Y73F, Y138A, and Y139A decreased hNAA50 activity to
undetectable levels21. For hNAA50-M75A and -I142A, we
observed increased activity when bound to hNatA to form the
hNatE complex, as we observed for hNAA50-WT. As expected,
the hNatE/HYPK complex displayed reduced activity compared
to both hNAA50 alone and hNatE. However, we observed that
hNatE-M75A/HYPK and hNatE-I142A/HYPK exhibited simi-
lar activity, compared to their corresponding hNAA50 mutants
alone. These data are consistent with the conclusion that per-
turbation of the hNAA50 β3−β4 and β6−β7 loops within the
hNatE/HYPK complex underlies the observed reduced catalytic
efficiency of hNatE in the presence of HYPK.
Discussion
While the interaction and catalytic crosstalk within NatE in the
yeast system had previously been reported, the corresponding
human system and the influence of HYPK binding on hNatE
activity had not previously been characterized. Here, we bio-
chemically and structurally characterize the mechanistic interplay








































Fig. 5 Subunit crosstalk within the hNatE complex. a hNAA50(magenta), hNAA15(green), and hNAA10(orange) within the hNatE complex overlay with
ScNatE (gray, PDB: 6O07). The α3 helix and β7 strand of Naa50 is shown to shift toward Naa10 in the human structure (b) hNatE aligned with hNatA (light
blue, PDB:6C9M) and hNAA50 (wheat, PDB: 3TFY). The top zoom-in area shows the alignment of free hNAA50 and hNatE. The below zoom-in area
shows the hNAA10 conformational change induced by hNAA50 binding.
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complex, and the role of HYPK in regulating hNatE activity.
Similar to the crystal structure of ScNatE (PDB: 6O07), we find
that hNAA50 binds hNatA mainly through hNAA15, using
highly conserved residues, including a key threonine residue
located at the center of the binding interface. Notably, the dis-
tance between hNAA50 and hNAA10 in the human complex is
significantly shorter than in the yeast complex. We find that these
two acidic hNAA50 residues, Glu7 and Asp53 contact two
hNAA10 arginine residues, inducing a conformational change in
hNAA10, which contributes to a decrease in hNatA enzymatic
activity.
While both hNAA50 and hNatA are conserved from yeast to
human, it had long been considered that HYPK is not present in
yeast until the recently identified HYPK in thermophilic fungus
Chaetomium thermophilum44. Nevertheless, it appears that evo-
lutionarily NAA50 appeared as a NatA-binding partner earlier
than HYPK did. In both budding and fission yeast, NAA50 is
inactive but regulates NatA acetylation activity46. While in higher
eukaryotes, NAA50 is enzymatically active, either with or without
NatA15,21. Thus, within the higher eukaryotic tetrameric NatE/
HYPK complex, it is likely that the regulation of NatA activity by
NAA50 was replaced by HYPK.
Here, we have reconstituted the tetrameric hNatE/HYPK
complex to demonstrate that HYPK and hNAA50 can bind to
hNatA simultaneously. We also confirmed the physiological
relevance of the tetrameric hNatE/HYPK complex through
immunoprecipitation of the complex from HeLa cells. We find
that while HYPK inhibits hNatA activity directly, it also indir-
ectly, but less potently, inhibits hNatE. We also find that hNAA50
and HYPK exhibit negative cooperativity with respect to hNatA
binding in vitro and in vivo. The structure of the hNatE/HYPK
complex suggests that this is due to the ability of the hNAA50 and
HYPK protein to bind to the hNAA15 subunit of hNatA in a way
that indirectly destabilizes binding of the other protein. This
observation, together with our findings that HYPK has a domi-
nant regulatory effect on hNatA activity relative to hNAA50 may
explain why excess free hNAA50 is observed over hNatA in
higher organism and HeLa cells48.
The nanomolar dissociation constants of HYPK and hNAA50
for hNatA is consistent, with our immunoprecipitation of the
tetrameric hNatE/HYPK complex from cells. The previous stu-
dies in Drosophila also reported that a dNAA50 knockout
decreases in vivo dNatA catalytic activity in the presence of
HYPK45. In terms of the biological function of this tetrameric
complex, we propose two non-mutually exclusive regulatory
mechanism for how hNAA50 protein levels could affect hNatA
activity. First, since hNAA50 has a negative effect on binding
between hNatA and HYPK, the absence of hNAA50, would
promote HYPK binding to hNatA to inhibit hNatA activity.
Second, since a recent yeast NatE-ribosome structure demon-
strated that yeast NAA50 participates in ribosome association49,
it is likely that hNAA50 in higher eukaryotes also contributes to
the association between tetrameric hNatE/HYPK and ribosome.
The lower level of hNAA50 could therefore decrease the fraction
of ribosome-associated hNatA to regulate its co-translational
activity.
The overall structures of hNAA50 and ScNAA50 are well con-
served with a mix of α-helices and β-strands. However, the overlay
of hNatE and ScNatE suggested that NAA50 shifts closer to NAA10






















































Fig. 6 Overall structure of the hNatE/HYPK complex. a hNAA50 (pink), hNAA15 (green), hNAA10 (orange), and HYPK (red) within the hNatE complex
is shown in cartoon. b Zoom-in view of the contacts between HYPK and hNAA15 with residues that participate in interaction shown. c Zoom-in view of the
contacts between hNAA15 and hNAA50 with residues that participate in interaction shown. d Zoom-in view of the contacts between hNAA10 and
hNAA50 with residues that participate in interaction shown.
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human system NAA10 and NAA50 have more intimate contact
and crosstalk in enzymatic activity. However, the previous data
indicated that the degree of NAA50 and NAA10 activity crosstalk is
similar in yeast and human46. In a recently reported yeast ScNatE-
ribosome structure, the ScNAA10 and ScNAA50 catalytic sites are
50 Å and 85Å away from the peptide exit site on the ribosome49.
While unlike ScNAA50, hNAA50 is co-translationally enzymati-
cally active15. Thus, we propose that this shift of NAA50 closer to
NAA10 in the human over the yeast complex may have an impact
on the relative distance between the nascent chain and active sites of
hNAA10 and hNAA50.
With respect to hNatA binding to the ribosome, it is possible
that HYPK may also contribute to ribosome binding by hNatA.
This could then indirectly affect hNAA50 recruitment to the
ribosome, which would be promoted by hNatA but inhibited by
HYPK. HYPK contains a UBA domain, which is also present at
the C-terminus of the alpha subunit of the nascent polypeptide-
associated complex. Further studies are required to test these
hypotheses for hNatA recruitment to the ribosome.
The hNatE/HYPK complex co-translationally acetylates nas-
cent peptides with N-termini of either methionine maintained or
cleaved, which accounts for the largest number of substrates
among all NATs. Given that this complex acetylates ~40–60% of
the human proteome and has altered function in many human
diseases, the studies presented here provides an important
molecular scaffold for potential therapeutic development.
Methods
Plasmid construction. A mammalian expression vector pcDNA3.1/NAA15-V5 was








































































Fig. 7 Molecular basis for hNAA50 and HYPK binding to hNatA. a hNatE/HYPK overlayed onto hNatE (purple) with NAA50 aligned. b hNatE/HYPK
overlayed onto hNatA/HYPK (PDB: 6C95, blue) with HYPK aligned. c Zoom-in view of HYPK C-terminal binding region as indicated in a. d Zoom-in view
of HYPK α2 binding region as indicated in a. e Zoom-in view of HYPK N-terminal α1 domain binding region as indicated in a. f Zoom-in view shows the
hNAA50 binding region on hNAA15 as indicated in b. g Zoom-in view shows the hNAA50 binding region on hNAA10 as indicated in b. h Zoom-in view
shows the hNAA15 C-terminal helices conformal changes when HYPK bound as indicated in b.
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England Biolabs) to encode hNAA15 variants c.1216-1218ACA >TAC (p.T406Y) and
c.2441 T > C (p.L814P). Primer sequences for p.T406Y are AAGTACACCTTACTTA
ATAGAACTCTTTCTCGTG and TCAATAGCAGTATTTATGTAC. Primer sequences
for p.L814P are TGATGGTAGCCCAGGAGACTGTA and TACAAGGCTTCCAATA
CC. The mutated plasmid sequences were verified by sequencing.
Proteomics sample preparation of NAA15-V5 immunoprecipitates. For
immunoprecipitation of NAA15-V5 variants, two 10 cm dishes of HeLa cells (ATCC
CCL-2) were transfected with 10 µg of either pcDNA3.1/NAA15-WT-V5, pcDNA3.1/
NAA15-T406Y-V5, or pcDNA3.1/NAA15-L814P-V5 using X-tremeGENE™ 9 DNA
Transfection Reagent (Roche). The growth medium was replaced after 24 h. Forty
eight hours post transfection, cells were harvested and lysed in 200 µl IPH lysis buffer
(50mM Tris-HCl pH 8.0, 150mM NaCl, 5mM EDTA, 0.5% NP-40, 1× complete
EDTA-free protease inhibitor cocktail (Roche)) per cell dish for 15min at 4 °C on a
rotating wheel. Cell debris was pelleted by centrifugation (17,000 × g, 4 °C, 5min) and
the supernatant was mixed with 2 µg of V5-tag mouse monoclonal antibody (Invi-
trogen, R960-25) and incubated for 2 h at 4 °C on a rotating wheel. Thereafter, 20 µl of
Dynabeads™ Protein G (Invitrogen) washed in IPH lysis buffer was added to the cell
lysates and incubated overnight. The next day, beads were washed three times in IPH
lysis buffer before the retrieved immunocomplexes were eluted in 60 µl FASP buffer
(2% SDS, 100mM Tris-HCl pH 7.6, and 0.1M dithiothreitol (DTT)) and heated for 5
min at 95 °C. Filter-aided sample preparation (FASP) method was performed to
process the eluates for liquid chromatography–MS/MS analysis50. The protein sam-
ples were mixed with 200 µl UA buffer (8M urea, 100 Mm Tris-HCl pH 8.0),
transferred to Microcon 30 kDa MWCO filters and centrifuged. All centrifugation
steps were carried out at 23 °C and 14,000 × g for 15min. The filters were washed
three times with 200 µl UA by spinning. Proteins were then Cys-alkylated by incu-
bation with 100 µl 50mM iodoacetamide (IAA) in UA for 20min, before IAA was
removed by centrifugation. Filters were then washed three times with 100 µl UA.
Finally, the UA buffer was exchanged by three washes with 100 µl 50mM ammonium
bicarbonate (ABC), before 500 ng trypsin (Sequencing Grade Modified Trypsin,
Promega) was added to the filters and incubated overnight at 37 °C. Digested proteins
were collected by centrifugation and the filter was washed once with 75 µl ABC.
Peptides were acidified with 5% formic acid (FA) and desalted using PierceTM C18-
Tips (Thermo Scientific) according to manufacturer´s protocol. The final eluates were
dried by speed vacuum and diluted to desired concentration with 5% FA.
MS analysis of NAA15-V5 immunoprecipitates. MS analysis was performed with
an Ultimate 3000 RSLC system (Thermo Scientific) coupled to a Q-Exactive HF mass
spectrometer (Thermo Scientific) equipped with EASY-spray nano-electrospray ion
source (Thermo Scientific). About 1 µg tryptic peptides were loaded and desalted on a
pre-column (Acclaim PepMap 100, 2 cm× 75 µm ID nanoViper column, packed with
3 µm C18 beads) with 0.1% trifluoroacetic acid (flow rate 5 µl/min, 5min). Peptides
were separated during a biphasic acetonitrile (ACN) gradient from two nanoflow
UPLC pumps (flow rate of 200 nl/min) on an analytical column (PepMap RSLC, 50
cm× 75 µm i.d. EASY-spray column, packed with 2 µm C18 beads). Solvent A and B
were 0.1% FA (vol/vol) in water and 100% ACN, respectively. The gradient com-
position was 5% B for 5min, 5–8% B for 0.5min, 8–24% B for 109.5min, 24–35% B
for 25min, and 35–80% B for 15min, 80% B over 15min for isocratic elution and 5%
B over 20min for conditioning. The eluting peptides were ionized in the electrospray
and analyzed by the Q-Exactive HF. The mass spectrometer was operated in data-
dependent mode to automatically switch between full scan MS and MS/MS acqui-
sition. MS spectra (m/z 375–1500) were obtained with a resolution of 120,000 at m/z
200, automatic gain control (AGC) target of 3 × 106 and maximum injection time
(IT) of 100ms. The 12 most intense peptides above a threshold of 50,000 counts and
charge states two to five were isolated (window of 1.6m/z, AGC target of 1 × 105 and
maximum IT of 110ms) for fragmentation at a normalized collision energy of 28%.
Fragments were detected in the orbitrap at a resolution of 15,000 atm/z 200, with first
mass fixed at m/z 100. Precursor masses selected for MS/MS analysis were excluded
by dynamic exclusion for 25 s with “exclude isotopes” enabled. Lock-mass internal
calibration (m/z 445.12003) was used. The raw data acquired was processed with
MaxQuant v. 1.6.2.6 and Andromeda search engine. The spectra were searched
against a database of Swiss-Prot annotated human protein sequences (2,0431
sequences, retrieved 25.06.2019) and a reverse decoy database. Cystein carbamido-
methylation was selected as a fixed modification and variable modifications included
methionine oxidation and protein N-terminal acetylation. The false discovery rate was
set to 1% for peptide and protein identification, minimum peptide length allowed was
seven and match between runs (0.7min match time window, 20min alignment time
window) was enabled. Label-free quantification51 and IBAQ were selected. All other
parameters were set to default values. The resulting proteingroups.txt file was ana-
lyzed using Perseus software v. 1.6.5.0. Proteins only identified by site, common
contaminants and reverse hits were filtered away. The IBAQ intensities of hNAA10,
hNAA50, and HYPK were normalized to the IBAQ intensity of NAA15 in each IP
sample. Thereafter, the IBAQ intensity of hNAA15, hNAA10, hNAA50, and HYPK
in each sample was normalized to the IBAQ intensity of the corresponding protein in
the hNAA15-WT-V5 IP sample.
[14C]-Ac-CoA-based acetylation and western blot analysis. In order to test the
NatA Nt-acetylation activity of hNAA15-T406Y and hNAA15-L815P variants,
immunoprecipitation of hNAA15-V5 was performed as described above with
minor adjustments. Five 10 cm dishes of HeLa cells (ATCC CCL-2) were trans-
fected with 8 µg pcDNA3.1/NAA15-WT-V5, 8 µg pcDNA3.1/NAA15-T406Y-V5, or
10 µg pcDNA3.1/NAA15-L814P-V5. NAA15-WT-V5 and NAA15-T406Y-V5 were
co-transfected with 2 µg of empty pcDNA3.1/V5 vector to ensure equal conditions
for the cells. As a negative control, five dishes of HeLa cells were transfected with
10 µg of pcDNA3.1/LacZ-V5. Immunoprecipitation from harvested and lysed cells
was performed using 3 µg of V5-tag mouse monoclonal antibody (Invitro-
gen, R960-25) and 30 µl of Dynabeads™ Protein G (Invitrogen). The beads were
washed three times in IPH lysis buffer and resuspended in 95 µl acetylation buffer
(50 mM Tris-HCl pH 8.5, 1 mM EDTA, 10% Glycerol). [14 C]-Ac-CoA-based Nt-
acetylation assays were performed as described52. In brief, three reaction mixture
replicates were prepared containing 10 µl of immunoprecipitated enzyme, 200 µM
synthetic 24-mer oligopeptide SESS24: NH2-SESSSKSRWGRPVGRRRRPVRVYP-
COOH (BioGenes), 50 µM [14C]-Ac-CoA (Perkin-Elmer), and acetylation buffer to
a final volume of 25 µl. Reaction mixtures without oligopeptide were used as
negative controls. The reaction mixtures were incubated at 37 °C at 1400 rpm
shaking for 30 min. The reaction was stopped by isolating beads on a magnet and
transferring 23 µl of the supernatant onto P81 phosphocellulose filter discs (Mil-
lipore). The filter discs were washed three times in 10 mM HEPES buffer (pH 7.4)
and air dried, before they were added to 5 ml Ultima Gold F scintillation mixture
(Perkin-Elmer) and the incorporated [14C]-Ac was measured by a Perkin-Elmer
TriCarb 2900TR Liquid Scintillation Analyzer. The immunoprecipitate input was
determined by Western blot analysis. Proteins were separated by SDS–PAGE,
transferred onto a nitrocellulose membrane (Amersham Protran 0.2 µM NC), and
probed with V5-tag mouse monoclonal antibody (1:5000, Invitrogen, R960-25) and
NAA10 rabbit monoclonal antibody (1:1000, Cell Signaling #13357). Protein bands
were imaged by ChemiDocTM XRS+ system (Bio-Rad) and quantified using









Fig. 8 Molecular basis for the decrease of hNAA50 activity by HYPK. hNatE/HYPK (green) overlayed onto hNatE (magenta) with hNatA aligned. Zoom-
in view shows the local conformational change of hNAA50.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-14584-7 ARTICLE
NATURE COMMUNICATIONS |          (2020) 11:818 | https://doi.org/10.1038/s41467-020-14584-7 | www.nature.com/naturecommunications 11
signal for each reaction was normalized to the amount of NAA15-V5 in the
respective IP sample.
Protein expression and purification. N-his-tagged hNatA and N-his-tagged
hNatA/HYPK were expressed in sf9 cells (ThermoFisher, cat #12659017) and purified
as described previously16. hNAA5021 and MBP-HYPK16 were expressed in BL21
(DE3) Escherichia coli cells (Thermo Scientific) and Rosetta (DE3)pLysS E. coli cells
(Millipore Sigma), respectively, and purified as described previously16. For hNatA and
hNatA/HYPK sf9 expression, high density (2 × 106 cells ml−1) suspension cultures of
Sf9 cells were infected at a multiplicity of infection of 1 for 48 h in Fernbach Shake
flasks at 27 °C. Cell pellets were resuspended in lysis buffer of 25mM Tris, pH 8.0,
500mM NaCl, 10mM imidazole, 10 mM β-mercaptoethanol (β-ME), 10mgml−1
PMSF (phenylmethanesulfonylfluoride), DNase, and complete, EDTA-free protease
inhibitor tablet (Roche). After sonication, clarified lysate was passed on nickel resin
(Thermo Scientific), washed with 10 column volumes (CV) of lysis buffer, and eluted
with 25mM Tris, pH 8.0, 200mM NaCl, 200mM imidazole, and 10mM β-ME. The
elutent was further purified on a HiTrap SP ion-exchange column with a salt gradient
(200mM to 1M NaCl). Peak fractions were pooled and run on a Superdex 200
Increase 10/300 GL gel filtration column in sizing buffer containing 25mM HEPES,
pH 7.0, 200mM NaCl, and 1mM tris-2-carboxyethyl)phosphine (TCEP). Peak
fractions were pooled and flash-frozen for storage in −80 °C until use.
For E. coli protein expression, transformed cells were cultured at 37 °C until the
absorbance A600 reached ~0.7, induced with 0.5 mM IPTG (isopropyl 1-thio-β-d-
galactopyranoside), and grown overnight at 16 °C. E.coli cells overexpressing MBP-
HYPK were lysed in 25 mM Tris, pH 8.0, 150 mM NaCl, 10 mM β-ME, and 10 mg
ml−1 PMSF. Clarified lysate was passed on to amylose agarose resin (New England
Biolabs), washed with lysis buffer, and eluted in lysis buffer supplementaed with
20 mM maltose. Eluted protein was purified with a 5 ml HiTrap Q ion-exchange
column (GE Healthcare) in the same buffer with a gradient (150 mM to 1M NaCl).
Peak fractions were pooled and loaded to a Superdex-75 Increase 10/300 GL gel
filtration column (GE Healthcare) in buffer of 25 mM HEPES, pH 7.0, 200 mM
NaCl, and 1 mM TCEP. Peak fractions were pooled and flash-frozen for storage
in −80 °C until use. E. coli cells overexpressing GST-tagged NAA50 were lysed
in 25 mM HEPES pH 7.5, 100 mM NaCl, and 10 mM β-ME by sonication. The
supernatant was isolated and loaded to GST-binding resin (Clontech), washed with
10 CV lysis buffer. Tobacco etch virus protease was added to the resin for on-
column cleavage overnight at room temperature. Untagged Naa50 was eluted from
the column with lysis buffer and collected for overnight dialysis in buffer with
25 mM HEPES (pH 7.5), 50 mM NaCl, and 10 mM β-ME. Ion exchange was
carried out with a 5-ml HiTrap SP ion exchange column (GE Healthcare) with
a gradient of 50–750 mM NaCl. Peak fractions were further purified using a
Superdex-75 gel filtration column (GE Healthcare) to homogeneity in buffer
containing 25 mM HEPES, pH 7.5, 100 mM NaCl, and 10 mM DTT. Protein was
flash-frozen for storage in −80 °C until use.
Protein harboring mutations was generated with the QuickChange protocol
(Stratagene)53 and obtained following the same expression and purification
protocol as described for the WT protein. Primers for making mutations were as
follows; hNAA50-E7A: AAGGTAGCCGGATCGCGCTGGGAGATGTG and CAC
ATCTCCCAGCGCGATCCGGCTACCTT; hNAA50-D53A: CTTGCCTATTTCAAT
GCTATTGCTGTAGGTGC and GCACCTACAGCAATAGCATTGAAATAGGCAA
G; hNAA50-M75A: GACTTTACATCGCGACACTAGGATG and CATCCTAGTGT
CGCGATGTAAAGTC; hNAA50-Y138A: ACAAAGAAGAACGCCTATAAGAGGA
TAG and CTATCCTCTTATAGGCGTTCTTCTTTGT. The mutants hNAA5
0-Y73F, hNAA50-I142A, and hNAA50-Y139A were generated as previously
described21.
Acetyltransferase activity assays. Acetyltransferase assays were modified from
previous studies21,43 and carried out at room temperature in a reaction buffer
containing 75 mM HEPES, pH 7.0, 120 mM NaCl, and 1 mM DTT. The SASE
substrate peptide (NH2-SASEAGVRWGRPVGRRRRP-COOH; GenScript) and the
MLGP substrate peptide (NH2-MLGPEGGRWGRPVGRRRRP-COOH; GenScript)
were used to determine the enzymatic activity of hNatA and hNAA50, respectively.
Each curve was repeated at least three times. To test the effect of hNAA50 and
HYPK on hNatA activity, 100 nM of hNatA was mixed with 500 µM SASE peptide,
300 µM C14 labeled acetyl-CoA (4 mCi mmol−1; PerkinElmer Life Sciences), and
varied concentrations of hNAA50 or HYPK modulator were added for 12-minute
reactions. Signals were normalized against enzyme without modulator. For time
course activity assays, 500 nM of hNAA50, hNatE, or hNatE/HYPK were mixed
with 500 µM MLGP peptide, and 300 µM C14-labeled acetyl-CoA (4 mCi mmol−1;
PerkinElmer Life Sciences) in a 20 µl reaction volume. Only 15 µl of each reaction
mixture was quenched at specific times. For kinetic assays of hNAA50, hNatE and
hNatE/HYPK against MLGP peptide, 300 nM enzyme was mixed with 300 µM
C14-labeled acetyl-CoA (4 mCi mmol−1; PerkinElmer Life Sciences) and the con-
centration of the peptide substrate was varied for a 40-min reaction. Data were fit
to a Michaelis–Menten equation in GraphPad Prism for determination of kinetic
parameters.
FP binding assays. FP binding assays were performed essentially as described
previously46. A total of 10 nM of fluorescein labeled hNAA50 (ref. 46) was used in
all reactions, and hNatA or hNatA/MBP-HYPK concentrations were varied to
determine the Kd. A total of 5 mgml−1 bovine serum albumin and 0.2% v/v Tween
were added into the reaction buffer (25 mM HEPES, pH 7.0, 200 mM NaCl, and
10 mM DTT) to prevent non-specific binding. FP readings were taken with a
Perkin-Elmer EnVision and each curve was repeated in triplicate. GraphPad Prism
(version 5.01) was used for all data fitting to determine Kd. A single-site specific
binding model was used, with Eq. (1),
Fi ¼ F0 þ F1 ´
Kd þ M½  þ L½  
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi




where Fi is the fluorescence reading at ligand (either hNatA or hNatA/HYPK)
concentration [L]i; Kd is the equilibrium dissociation binding constant; [M] is the
concentration of hNaa50; F0 is the fluorescence reading extrapolated to no ligand;
and F1 is the maximum fluorescence increase at saturating ligand concentration. Fit
parameters for hNatA/HYPK(MBP tagged) binding were F0= 161.3 ± 3.3, F1=
222.0 ± 5.2, Kd= 127 ± 13 nM, and R2= 0.98. For hNatA, F0= 205.8 ± 4.4, F1=
137.2 ± 5.4, Kd= 46 ± 8.8 nM, and R2= 0.95.
ITC measurements. ITC measurements were carried out using a MicroCal iTC200
at 20 °C. Samples were dialyzed into buffer containing 25 mM HEPES pH 7.0,
200 mM NaCl, and 1 mM DTT. Protein samples (hNatA and hNatE) with con-
centrations of 15 μM in the cell and 150 μM of MBP-HYPK in the syringe were
used in the experiments. The raw data were analyzed with the MicroCal ITC
analysis software.
Cryo-EM sample preparation and data collection. To prepare hNatE complex,
purified hNatA and three molar excess of hNAA50 were mixed and loaded onto a
Superdex 200 10/30 GL column (GE Healthcare). Peak fractions with all subunits
present, as confirmed with SDS–PAGE analysis, were concentrated to 1 mgml−1.
Fresh sample incubated with three molar excess of both hNatA and hNAA50 bi-
substrate analogs for ~30 min on ice was applied to Quantinfoil R1.2/1.3 holey
carbon support grids. To prepare hNatE/HYPK complex, purified hNatA/HYPK
and three molar excess of hNAA50 were mixed and loaded onto an S200 gel
filtration column (GE Healthcare). Peak fractions with all subunits present, as
confirmed with SDS–PAGE were concentrated to 1 mgml−1. Fresh sample with
three molar excess of acetyl-CoA and hNAA50 bi-substrate analogs for ~30 min in
ice was applied to Quantinfoil R1.2/1.3 holey carbon support grids.
Both sample grids were blotted for 10–12 s (blot force= 2) under 100%
humidity at 16 °C before the sample was plunged into liquid ethane, using a FEI
Vitrobot Mark IV. An FEI TF20 was used for screening the grids and data
collection was performed either with a Talos Arctica microscope or Titan Krios
equipped with a K2 Summit direct detector (Gatan).
Cryo-EM data processing. Original image stacks were summed and corrected for
drift and beam-induced motion at the micrograph level using MotionCor2 (ref. 54).
Defocus estimation and the resolution range of each micrograph were performed
with Gctf55. For hNatA/hNAA50, ~3000 particles were manually picked to gen-
erate several rough two-dimensional (2D) class averages. Representative 2D classes
were used to autopick ~1,229,331 particles from 4025 micrographs using Relion56.
All particles were extracted and binned to accelerate the 2D and three-dimensional
(3D) classifications. After bad particles were further removed by 2D and 3D
classification, 353,541 particles were used for auto refinement, particle polishing,
and per particle contrast transfer function (CTF) refinement. The final map of the
hNatE complex was refined to an overall resolution of 3.02 Å, with local resolution
estimated by Resmap57. For the hNatE/HYPK complex, image processing workflow
was similar as described above. A total of 477,608 particles were picked from 1004
micrographs and 168,536 particles were used for refinement. The final resolution of
the hNatE/HYPK complex was 4.03 Å.
Cryo-EM model building and refinement. For hNatE model building, the crystal
structures of hNatA (PDB: 6C9M) and hNAA50(PDB: 3TFY) were fit into the
3.02 Å EM map as rigid bodies, followed by manual adjustment in coot58 and real-
space refinement in PHENIX59. For the hNatE/HYPK model building, the crystal
structure of hNatA/HYPK (PDB: 6C95) and hNAA50 (PDB: 3TFY) were used. All
representations of cryo-EM density and structural models were performed with
Chimera60 and PyMol (The PyMOL Molecular Graphics System, Version 1.2r3pre,
Schrödinger, LLC).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The cryo-EM map for the hNatE and hNatE/HYPK and the respective atomic
coordinates have been deposited in the EMDataBnak and ProteinDataBank, with
accession codes of EMD-20442 and 6PPL for hNatE, respectively, and with EMD-20501
and 6PW9 for hNatE/HYPK, respectively. The mass spectrometry datasets have been
deposited to the ProteomeXchange/PRIDE member repository under the PDX accession
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code PXD017031. The source data for Table 1, Figs. 1b, 2a–d, 3a, b, and Supplementary
Fig. 2 are provided in the Source Data file.
Received: 19 June 2019; Accepted: 18 January 2020;
References
1. Aksnes, H., Drazic, A., Marie, M. & Arnesen, T. First things first: vital protein
marks by N-terminal acetyltransferases. Trends Biochem. Sci. 41, 746–760
(2016).
2. Arnesen, T. et al. Proteomics analyses reveal the evolutionary conservation
and divergence of N-terminal acetyltransferases from yeast and humans. Proc.
Natl Acad. Sci. USA 106, 8157–8162 (2009).
3. Scott, D. C., Monda, J. K., Bennett, E. J., Harper, J. W. & Schulman, B. A. N-
terminal acetylation acts as an avidity enhancer within an interconnected
multiprotein complex. Science 334, 674–678 (2011).
4. Yang, D. et al. Nα-acetylated Sir3 stabilizes the conformation of a nucleosome-
binding loop in the BAH domain. Nat. Struct. Mol. Biol. 20, 1116–1118
(2013).
5. Dikiy, I. & Eliezer, D. N-terminal acetylation stabilizes N-terminal helicity in
lipid- and micelle-bound alpha-synuclein and increases its affinity for
physiological membranes. J. Biol. Chem. 289, 3652–3665 (2014).
6. Holmes, W. M., Mannakee, B. K., Gutenkunst, R. N. & Serio, T. R. Loss of
amino-terminal acetylation suppresses a prion phenotype by modulating
global protein folding. Nat. Commun. 5, 4383 (2014).
7. Forte, G. M., Pool, M. R. & Stirling, C. J. N-terminal acetylation inhibits
protein targeting to the endoplasmic reticulum. PLoS Biol. 9, e1001073
(2011).
8. Srinivasan, S. et al. Hypoxia-induced expression of phosducin-like 3 regulates
expression of VEGFR-2 and promotes angiogenesis. Angiogenesis 18, 449–462
(2015).
9. Arnesen, T. Towards a functional understanding of protein N-terminal
acetylation. PLoS Biol. 9, e1001074 (2011).
10. Shemorry, A., Hwang, C. S. & Varshavsky, A. Control of protein quality and
stoichiometries by N-terminal acetylation and the N-end rule pathway. Mol.
Cell 50, 540–551 (2013).
11. Aksnes, H., Ree, R. & Arnesen, T. Co-translational, post-translational, and
non-catalytic roles of n-terminal acetyltransferases. Mol. Cell 73, 1097–1114
(2019).
12. Dinh, T. V. et al. Molecular identification and functional characterization of
the first Nalpha-acetyltransferase in plastids by global acetylome profiling.
Proteomics 15, 2426–2435 (2015).
13. Polevoda, B. & Sherman, F. Composition and function of the eukaryotic N-
terminal acetyltransferase subunits. Biochem. Biophys. Res. Commun. 308,
1–11 (2003).
14. Gautschi, M. et al. The yeast N(alpha)-acetyltransferase NatA is quantitatively
anchored to the ribosome and interacts with nascent polypeptides. Mol. Cell
Biol. 23, 7403–7414 (2003).
15. Evjenth, R. et al. Human Naa50p (Nat5/San) displays both protein N alpha-
and N epsilon-acetyltransferase activity. J. Biol. Chem. 284, 31122–31129
(2009).
16. Gottlieb, L. & Marmorstein, R. Structure of human NatA and its regulation
by the huntingtin interacting protein HYPK. Structure 26, 925–935 e928
(2018).
17. Van Damme, P. et al. N-terminal acetylome analyses and functional insights
of the N-terminal acetyltransferase NatB. Proc. Natl Acad. Sci. USA 109,
12449–12454 (2012).
18. Hong, H. et al. Molecular basis of substrate specific acetylation by N-terminal
acetyltransferase NatB. Structure 25, 641–649 e643 (2017).
19. Van Damme, P. et al. A role for human N-alpha acetyltransferase 30 (Naa30)
in maintaining mitochondrial integrity. Mol. Cell Proteom. 15, 3361–3372
(2016).
20. Van Damme, P. et al. NatF contributes to an evolutionary shift in protein N-
terminal acetylation and is important for normal chromosome segregation.
PLoS Genet. 7, e1002169 (2011).
21. Liszczak, G., Arnesen, T. & Marmorstein, R. Structure of a ternary Naa50p
(NAT5/SAN) N-terminal acetyltransferase complex reveals the molecular
basis for substrate-specific acetylation. J. Biol. Chem. 286, 37002–37010
(2011).
22. Stove, S. I. et al. Crystal structure of the golgi-associated human Nalpha-
acetyltransferase 60 reveals the molecular determinants for substrate-specific
acetylation. Structure 24, 1044–1056 (2016).
23. Song, O. K., Wang, X., Waterborg, J. H. & Sternglanz, R. An Nalpha-
acetyltransferase responsible for acetylation of the N-terminal residues of
histones H4 and H2A. J. Biol. Chem. 278, 38109–38112 (2003).
24. Magin, R. S., Liszczak, G. P. & Marmorstein, R. The molecular basis for
histone H4- and H2A-specific amino-terminal acetylation by NatD. Structure
23, 332–341 (2015).
25. Drazic, A. et al. NAA80 is actin’s N-terminal acetyltransferase and regulates
cytoskeleton assembly and cell motility. Proc. Natl Acad. Sci. USA 115,
4399–4404 (2018).
26. Goris, M. et al. Structural determinants and cellular environment define
processed actin as the sole substrate of the N-terminal acetyltransferase
NAA80. Proc. Natl Acad. Sci. USA 115, 4405–4410 (2018).
27. Polevoda, B., Brown, S., Cardillo, T. S., Rigby, S. & Sherman, F. Yeast N
(alpha)-terminal acetyltransferases are associated with ribosomes. J. Cell
Biochem. 103, 492–508 (2008).
28. Aksnes, H. et al. An organellar nalpha-acetyltransferase, naa60, acetylates
cytosolic N termini of transmembrane proteins and maintains Golgi integrity.
Cell Rep. 10, 1362–1374 (2015).
29. Aksnes, H. et al. Molecular determinants of the N-terminal acetyltransferase
Naa60 anchoring to the Golgi membrane. J. Biol. Chem. 292, 6821–6837
(2017).
30. Dorfel, M. J. & Lyon, G. J. The biological functions of Naa10 - From amino-
terminal acetylation to human disease. Gene 567, 103–131 (2015).
31. Lee, C. F. et al. hNaa10p contributes to tumorigenesis by facilitating DNMT1-
mediated tumor suppressor gene silencing. J. Clin. Invest. 120, 2920–2930
(2010).
32. Yoon, H. et al. NAA10 controls osteoblast differentiation and bone formation
as a feedback regulator of Runx2. Nat. Commun. 5, 5176 (2014).
33. Saunier, C. et al. Expanding the Phenotype Associated with
NAA10-Related N-Terminal Acetylation Deficiency. Hum. Mutat. 37,
755–764 (2016).
34. Popp, B. et al. De novo missense mutations in the NAA10 gene cause severe
non-syndromic developmental delay in males and females. Eur. J. Hum.
Genet. 23, 602–609 (2015).
35. Esmailpour, T. et al. A splice donor mutation in NAA10 results in the
dysregulation of the retinoic acid signalling pathway and causes Lenz
microphthalmia syndrome. J. Med. Genet. 51, 185–196 (2014).
36. Casey, J. P. et al. NAA10 mutation causing a novel intellectual disability
syndrome with long QT due to N-terminal acetyltransferase impairment. Sci.
Rep. 5, 16022 (2015).
37. Cheng, H. et al. Phenotypic and biochemical analysis of an international
cohort of individuals with variants in NAA10 and NAA15. Hum. Mol. Genet.
28, 2900–2919 (2019).
38. Ree, R. et al. A novel NAA10 p.(R83H) variant with impaired acetyltransferase
activity identified in two boys with ID and microcephaly. BMC Med. Genet.
20, 101 (2019).
39. Rope, A. F. et al. Using VAAST to identify an X-linked disorder resulting in
lethality in male infants due to N-terminal acetyltransferase deficiency. Am. J.
Hum. Genet. 89, 28–43 (2011).
40. Kalvik, T. V. & Arnesen, T. Protein N-terminal acetyltransferases in cancer.
Oncogene 32, 269–276 (2013).
41. Arnesen, T. et al. The chaperone-like protein HYPK acts together with NatA
in cotranslational N-terminal acetylation and prevention of Huntingtin
aggregation. Mol. Cell Biol. 30, 1898–1909 (2010).
42. Arnesen, T. et al. Cloning and characterization of hNAT5/hSAN: an
evolutionarily conserved component of the NatA protein N-alpha-
acetyltransferase complex. Gene 371, 291–295 (2006).
43. Liszczak, G. et al. Molecular basis for N-terminal acetylation by the
heterodimeric NatA complex. Nat. Struct. Mol. Biol. 20, 1098–1105
(2013).
44. Weyer, F. A. et al. Structural basis of HypK regulating N-terminal acetylation
by the NatA complex. Nat. Commun. 8, 15726 (2017).
45. Rathore, O. S. et al. Absence of N-terminal acetyltransferase diversification
during evolution of eukaryotic organisms. Sci. Rep. 6, 21304 (2016).
46. Deng, S. et al. Structure and Mechanism of Acetylation by the N-
Terminal Dual Enzyme NatA/Naa50 Complex. Structure 27, 1057–1070 e1054
(2019).
47. Caro, J. A. et al. Entropy in molecular recognition by proteins. Proc. Natl
Acad. Sci. USA 114, 6563–6568 (2017).
48. Hou, F., Chu, C. W., Kong, X., Yokomori, K. & Zou, H. The acetyltransferase
activity of San stabilizes the mitotic cohesin at the centromeres in a
shugoshin-independent manner. J. Cell Biol. 177, 587–597 (2007).
49. Knorr, A. G. et al. Ribosome-NatA architecture reveals that rRNA expansion
segments coordinate N-terminal acetylation. Nat. Struct. Mol. Biol. 26, 35–39
(2019).
50. Wisniewski, J. R., Zougman, A., Nagaraj, N. & Mann, M. Universal
sample preparation method for proteome analysis. Nat. Methods 6, 359–362
(2009).
51. Cox, J. et al. Accurate proteome-wide label-free quantification by delayed
normalization and maximal peptide ratio extraction, termed MaxLFQ. Mol.
Cell Proteom. 13, 2513–2526 (2014).
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-14584-7 ARTICLE
NATURE COMMUNICATIONS |          (2020) 11:818 | https://doi.org/10.1038/s41467-020-14584-7 | www.nature.com/naturecommunications 13
52. Drazic, A. & Arnesen, T. [(14)C]-Acetyl-coenzyme a-based in vitro n-terminal
acetylation assay. Methods Mol. Biol. 1574, 1–8 (2017).
53. Braman, J., Papworth, C. & Greener, A. Site-directed mutagenesis using
double-stranded plasmid DNA templates. Methods Mol. Biol. 57, 31–44
(1996).
54. Zheng, S. Q. et al. MotionCor2: anisotropic correction of beam-induced
motion for improved cryo-electron microscopy. Nat. Methods 14, 331–332
(2017).
55. Zhang, K. Gctf: Real-time CTF determination and correction. J. Struct. Biol.
193, 1–12 (2016).
56. Kimanius, D., Forsberg, B. O., Scheres, S. H. & Lindahl, E. Accelerated cryo-
EM structure determination with parallelisation using GPUs in RELION−2.
ELife 5, e18722 (2016).
57. Kucukelbir, A., Sigworth, F. J. & Tagare, H. D. Quantifying the local resolution
of cryo-EM density maps. Nat. Methods 11, 63–65 (2014).
58. Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics.
Acta Crystallogr. D Biol. Crystallogr. 60, 2126–2132 (2004).
59. Adams, P. D. et al. PHENIX: a comprehensive Python-based system for
macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66,
213–221 (2010).
60. Pettersen, E. F. et al. UCSF Chimera–a visualization system for exploratory
research and analysis. J. Comput. Chem. 25, 1605–1612 (2004).
Acknowledgements
This work was supported by NIH grant R35 GM118090 awarded to R.M. T.A was
supported by the Research Council of Norway (Project 249843), the Norwegian Health
Authorities of Western Norway (Project 912176), the Norwegian Cancer Society, and the
European Research Council (ERC) under the European Union Horizon 2020 Research
and Innovation Program under grant agreement 772039. Parts of the work was carried
out at the Proteomics Unit at University of Bergen (PROBE). We acknowledge the
support of the Perelman School of Medicine, University of Pennsylvania DNA
Sequencing Core Facility and E. Dean from the High-Throughput Screening Core
Facility for providing the Sf9 cells containing human NatE for this study. We thank Zuo
Biao and Sudheer Molugu from Electron Microscopy Resource Lab of University of
Pennsylvania for the help of initial cryo-grids screening; Chen Xu, KangKang Song, and
Kyounghwan Lee from the University of Massachusetts Medical School Cryo-EM Core
Facility for technical assistance on data collection; and Dan Ricketts, Adam Olia, Austin
Vogt, and Leah Gottlieb for helpful discussions.
Author contributions
Conceptualization, S.D. and R.M.; methodology, S.D., N.M., X.W., T.A. and R.M.;
investigation, S.D., N.M. and X.W.; formal analysis, S.D., N.M. and X.W.; writing—
original draft, S.D.; visualization, S.D.; writing—review and editing, S.D., N.M., X.W.,
T.A. and R.M.; funding acquisition; T.A. and R.M.; resources, T.A. and R.M.; supervision,
T.A. and R.M.
Competing interest
The authors declare no competing interests.
Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41467-
020-14584-7.
Correspondence and requests for materials should be addressed to R.M.
Peer review information Nature Communications thanks the anonymous reviewers for
their contribution to the peer review of this work. Peer reviewer reports are available.
Reprints and permission information is available at http://www.nature.com/reprints
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2020
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-14584-7
14 NATURE COMMUNICATIONS |          (2020) 11:818 | https://doi.org/10.1038/s41467-020-14584-7 | www.nature.com/naturecommunications
